ecrin-mdr-crcClinical2016IPD Sharing (as of January 2022): NoColorectal NeoplasmsColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2198817United States3ImmunotherapyLiver lesionMEDI6469Anti-OX40 antibodyMetastatic colorectal cancerECRIN MDRTerminatedfalseAnti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal CancerThis study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.2016-03-152198817NCT02559024